Implanon
etonogestrel
Treatment for ContraceptionAkzo Nobel’s Contraceptive Implanon Receives “approvable” Status from the FDA
ARNHEM, The Netherlands, November 3, 2004 – Akzo Nobel’s human pharmaceutical business Organon announced today that the U.S. Food and Drug Administration (FDA) has granted the contraceptive Implanon (etonogestrel sub-dermal implant) “approvable” status.
Implanon is a small, flexible rod, about the size of a matchstick, that contains etonogestrel, a progestin. Once inserted under the skin, the rod continually releases a low dose of etonogestral into the bloodstream, which provides contraceptive protection. Implanon is one of the innovative contraceptive products developed by Organon in recent years.
“Organon recognizes the market need for diversity in the contraceptive marketplace and Implanon will provide women in the U.S. with a new method of contraception,” said Toon Wilderbeek, President of Organon International and Member of Akzo Nobel’s Board of Management.
For more information, please visit www.organon.com
Related Articles:
Implanon Organon - Treatment for Contraception - July 18, 2006
Organon Receives Approvable From FDA for Contraceptive Implant - June 21, 2005
New Drug Applications Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
